Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
...eatment...
...ommendations on Extended Therapy...
...with node-negative breast cancer a...
...node-positive breast cancer should be offere...
...extended adjuvant endocrine therapy shoul...
...ention of secondary or contralateral br...
...apy carries ongoing risks and side ef...
...ions on Ovarian Suppression...
...e Panel recommends that higher risk patients sho...
...ith Stage II or Stage III breast cancers who...
...h Stage I or II breast cancers at highe...
...th Stage I breast cancers not warran...
...ith node-negative cancers 1 centim...
...pression may be administered with eith...
...Recommended Pharmaceuticals for HR+...
...rognostic Factors for Recurrence After 5 Yea...